Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers.
In order to estimate the contribution of platelet-activating factor (PAF) to the formation of chronic subdural haematomas (CSH), we measured plasma PAF and anti-PAF antibody levels in head-injured patients with and without CSH and normal volunteers. Plasma PAF and anti-PAF IgG levels were higher in patients with CSH than in patients without CSH or in normal volunteers. Furthermore, plasma PAF and anti-PAF IgG levels increased in a time-dependent manner over the first 35 days following head injury. These data suggest that PAF may be involved in the generation of CSH.
Hirashima
Y
Y
Department of Neurosurgery, Toyama Medical and Pharmaceutical University, Japan.
Endo
S
S
Hayashi
N
N
Karasawa
K
K
Nojima
S
S
Takaku
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006408:Hematoma, Subdural / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010972:Platelet Activating Factor / Q000276:immunology* / Q000502:physiology*; D012016:Reference Values
D001323:Autoantibodies; D007074:Immunoglobulin G; D010972:Platelet Activating Factor